| Name | Title | Contact Details |
|---|
Tanenholz & Associates is a Washington, D.C. based law firm specializing in all aspects of discovery, from initial consultation to the end-to-end management of large-scale document reviews. With years of big-firm litigation experience, Tanenholz & Associates understands that well-planned and high quality document review can both minimize litigation costs and maximize litigation efficiencies. Providing flexible teams of skilled contract attorneys led by experienced senior associates, Tanenholz & Associates is uniquely equipped to manage your discovery needs.
Specializing in post-acquisition integration and restructuring, achieving operational excellence, supporting buyers like private equity firms with due diligence and deal dynamics, as well as coaching and development.
Wikifri is a nimble, aggressive, consulting firm founded by former Agile Technologies team members. We are focused on improving our clients businesses by bringing together deep insurance industry experience, the flexibility to build partnership-based engagement teams and technology expertise. Wikifri is founded by former Agile Technologies team members who are focused on a critical success factor to achieve breakthrough bottom line results for our clients by understanding their businesses and the difference they are going to make in their markets. We know successful technology investments help them achieve those goals. Our firms commitment to client success is demonstrated by our seasoned professionals industry experience, knowledge of the technology and insurance industry landscapes, and a long history of successful projects. Wikifri is committed to helping clients stay at the forefront of rapid industry changes by assisting them in the development of new markets and creating new efficiencies and capabilities for their organizations.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
PartnersFinancial is a member-centric network of successful, independent peers working together to drive life insurance sales. We harness, enable and spread the knowledge, insights and expertise of over 150 life insurance and diversified firms across the country. Our expertise is matched only by our personal commitment to each others and our clients goals.